Celnova announces market launch of LEVENOVA™ in Argentina
Celnova Pharma today announced that it has obtained the marketing authorization in Argentina for Levenova™ (Levetiracetam tablets, 500mg and 1000mg) from the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT). Levenova™ is now available in pharmacies across the country.
Levenova™ is part of Celnova Pharma’s growing Central Nervous System portfolio.
“We are excited about the launch of Levenova™, because it shows the commitment Celnova has in the area of Central Nervous System” said Juan Marrone, Celnova Pharma’s CEO.
“Manufactured under European Medicines Agency (EMA) standards, we believe Levenova™ has the best quality to cost ratio in the Argentine market” mentioned Héctor Coco Rodriguez, Neuroscience Manager at Celnova Pharma.
About Celnova Pharma
Celnova Pharma is a pharmaceutical company focused in complex therapeutic classes such as oncology, central nervous system and critical care. Celnova has established operations in Argentina and Chile, and is in the process of opening its Peru and Colombia subsidiaries.
Celnova’s business model combines branded generics with in-licensing of established drugs from multinational companies and patent-protected unique drugs.
Celnova’s long term goal is to grow in Latin America through a mix of organic growth and selected partnerships and acquisitions. For more information, please visit www.celnova.com.
Celnova Pharma is a registered trademark of Celnova Argentina S.A.